Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections

Japan’s health ministry pushed ahead with a decision to re-price Novartis Pharma’s anti-IgE antibody Xolair (omalizumab) following its label expansion into pollen allergy last year despite a big difference in its estimated patient number and the Swiss giant’s, Jiho has...read more